KR100270650B1 - 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료 - Google Patents

돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료 Download PDF

Info

Publication number
KR100270650B1
KR100270650B1 KR1019970704250A KR19970704250A KR100270650B1 KR 100270650 B1 KR100270650 B1 KR 100270650B1 KR 1019970704250 A KR1019970704250 A KR 1019970704250A KR 19970704250 A KR19970704250 A KR 19970704250A KR 100270650 B1 KR100270650 B1 KR 100270650B1
Authority
KR
South Korea
Prior art keywords
enzyme
dna
minutes
cells
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019970704250A
Other languages
English (en)
Korean (ko)
Inventor
존 테일러슨 크리스토퍼
요한네스 에겔테 헨드리쿠스
타라고나-피올 안토니오
로버트 라빈 브라이언
토마스 보일 프랜시스
프레더릭 헨남 존
찰스 블레이키 데이빗
로버트 마르샴 피터
윌리엄 히튼 데이빗
휴 데이비스 데이빗
마이클 슬레이터 앤소니
프랑소와 앙드레 에네퀸 로렝
Original Assignee
돈 리사 로얄
제네카 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100270650(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by 돈 리사 로얄, 제네카 리미티드 filed Critical 돈 리사 로얄
Application granted granted Critical
Publication of KR100270650B1 publication Critical patent/KR100270650B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
KR1019970704250A 1994-12-23 1995-12-21 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료 Expired - Fee Related KR100270650B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GB9426192.2 1994-12-23
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GB9516810.0 1995-08-16
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (1)

Publication Number Publication Date
KR100270650B1 true KR100270650B1 (ko) 2000-11-01

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970704250A Expired - Fee Related KR100270650B1 (ko) 1994-12-23 1995-12-21 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료

Country Status (23)

Country Link
US (1) US5985281A (https=)
EP (1) EP0806964B1 (https=)
JP (1) JP3805365B2 (https=)
KR (1) KR100270650B1 (https=)
CN (1) CN1095677C (https=)
AT (1) ATE222124T1 (https=)
AU (1) AU701916B2 (https=)
BR (1) BR9510490B1 (https=)
CA (1) CA2205091A1 (https=)
CZ (1) CZ195297A3 (https=)
DE (1) DE69527805T2 (https=)
ES (1) ES2181805T3 (https=)
FI (1) FI972683L (https=)
HU (1) HUT77450A (https=)
IL (1) IL116511A0 (https=)
MX (1) MX9704575A (https=)
NO (1) NO972882L (https=)
NZ (1) NZ297529A (https=)
PL (1) PL184031B1 (https=)
RU (1) RU2189251C2 (https=)
SK (1) SK80997A3 (https=)
TR (1) TR199501654A2 (https=)
WO (1) WO1996020011A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193278A (zh) 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1220864A4 (en) * 1999-09-17 2003-05-21 Genzyme Transgenics Corp TRANSGENICALLY PRODUCED FUSION PROTEINS
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (en) * 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) * 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU674137B2 (en) * 1992-01-30 1996-12-12 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
JP3805365B2 (ja) 2006-08-02
RU2189251C2 (ru) 2002-09-20
IL116511A0 (en) 1996-07-23
HUT77450A (hu) 1998-04-28
CZ195297A3 (en) 1997-12-17
US5985281A (en) 1999-11-16
AU701916B2 (en) 1999-02-11
PL184031B1 (pl) 2002-08-30
JPH10511547A (ja) 1998-11-10
MX9704575A (es) 1997-10-31
NO972882D0 (no) 1997-06-20
FI972683A0 (fi) 1997-06-19
FI972683A7 (fi) 1997-06-19
PL320964A1 (en) 1997-11-24
TR199501654A2 (tr) 1996-07-21
NO972882L (no) 1997-08-19
ATE222124T1 (de) 2002-08-15
WO1996020011A1 (en) 1996-07-04
FI972683L (fi) 1997-06-19
BR9510490B1 (pt) 2010-10-05
ES2181805T3 (es) 2003-03-01
CA2205091A1 (en) 1996-07-04
CN1095677C (zh) 2002-12-11
DE69527805D1 (de) 2002-09-19
BR9510490A (pt) 1998-01-13
TR199501654A3 (https=) 1996-07-21
NZ297529A (en) 1999-07-29
EP0806964B1 (en) 2002-08-14
CN1171054A (zh) 1998-01-21
DE69527805T2 (de) 2003-04-24
AU4269796A (en) 1996-07-19
SK80997A3 (en) 1998-02-04
EP0806964A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
KR100270650B1 (ko) 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료
US20020142359A1 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
US8993295B2 (en) Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
JP5150103B2 (ja) 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質
ES2493016T3 (es) Composiciones que comprenden anticuerpos contra CD79b conjugados a un agente inhibidor del crecimiento o un agente citotóxico y procedimientos para el tratamiento de tumores de origen hematopoyético
KR20010012441A (ko) 화합물
JP2006042821A (ja) 遺伝子指向性プロドラッグ療法における酵素の表面発現
US6436691B1 (en) Chemical compounds
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
CN121909216A (zh) 用于治疗酸性鞘磷脂酶缺乏症的抗TfR:酸性鞘磷脂酶
JP3735379B2 (ja) 複合体、その製造方法及びこれを含有する医薬組成物
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도
JP2002512774A (ja) 組換えオンコナーゼと、その化学的接合体および融合タンパク質

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20080716

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090805

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090805

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000